Shots:

• Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study
• The 1st part will evaluate the safety of the combination regimen while the 2nd part will assess the safety- tolerability- and anti-tumor activity in separate cohorts of subjects with HER2+ BC- HER2-low BC- and non-breast HER2-expressing solid tumors
• Zanidatamab is in the advanced clinical stage- actively enrolling a study in patients with prior treated HER2 gene-amplified BTC while five active P-II programs are underway. ALX148 is a next-generation CD47 blocker and has the potential to expand the chance for zanidatamab to benefits patients with HER2‑expressing BC

 ­ Ref: Zymeworks | Image: Medium